178 related articles for article (PubMed ID: 36351725)
1. Prostate MRI versus PSA screening for prostate cancer detection (the MVP Study): a randomised clinical trial.
Nam R; Patel C; Milot L; Hird A; Wallis C; Macinnis P; Singh M; Emmenegger U; Sherman C; Haider MA
BMJ Open; 2022 Nov; 12(11):e059482. PubMed ID: 36351725
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
3. Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial.
Björnebo L; Discacciati A; Falagario U; Vigneswaran HT; Jäderling F; Grönberg H; Eklund M; Nordström T; Lantz A
JAMA Netw Open; 2024 Apr; 7(4):e247131. PubMed ID: 38648061
[TBL] [Abstract][Full Text] [Related]
4. Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography: The IP1-PROSTAGRAM Study.
Eldred-Evans D; Burak P; Connor MJ; Day E; Evans M; Fiorentino F; Gammon M; Hosking-Jervis F; Klimowska-Nassar N; McGuire W; Padhani AR; Prevost AT; Price D; Sokhi H; Tam H; Winkler M; Ahmed HU
JAMA Oncol; 2021 Mar; 7(3):395-402. PubMed ID: 33570542
[TBL] [Abstract][Full Text] [Related]
5. The GÖTEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate.
Kohestani K; Månsson M; Arnsrud Godtman R; Stranne J; Wallström J; Carlsson S; Hellström M; Hugosson J
Scand J Urol; 2021 Apr; 55(2):116-124. PubMed ID: 33612068
[TBL] [Abstract][Full Text] [Related]
6. Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial.
Grenabo Bergdahl A; Wilderäng U; Aus G; Carlsson S; Damber JE; Frånlund M; Geterud K; Khatami A; Socratous A; Stranne J; Hellström M; Hugosson J
Eur Urol; 2016 Oct; 70(4):566-573. PubMed ID: 26724840
[TBL] [Abstract][Full Text] [Related]
7. Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial.
Tonttila PP; Lantto J; Pääkkö E; Piippo U; Kauppila S; Lammentausta E; Ohtonen P; Vaarala MH
Eur Urol; 2016 Mar; 69(3):419-25. PubMed ID: 26033153
[TBL] [Abstract][Full Text] [Related]
8. Repeated Prostate Cancer Screening Using Prostate-Specific Antigen Testing and Magnetic Resonance Imaging: A Secondary Analysis of the STHLM3-MRI Randomized Clinical Trial.
Nordström T; Annerstedt M; Glaessgen A; Carlsson S; Clements M; Abbadi A; Grönberg H; Jäderling F; Eklund M; Discacciati A
JAMA Netw Open; 2024 Feb; 7(2):e2354577. PubMed ID: 38324313
[TBL] [Abstract][Full Text] [Related]
9. Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only.
Hugosson J; Månsson M; Wallström J; Axcrona U; Carlsson SV; Egevad L; Geterud K; Khatami A; Kohestani K; Pihl CG; Socratous A; Stranne J; Godtman RA; Hellström M;
N Engl J Med; 2022 Dec; 387(23):2126-2137. PubMed ID: 36477032
[TBL] [Abstract][Full Text] [Related]
10. Can combined multiparametric magnetic resonance imaging of the prostate and prostate-specific antigen density improve the detection of clinically significant prostate cancer: A prospective single-center cross-sectional study.
Yadav K; Sureka B; Elhence P; Choudhary GR; Pandey H; Garg PK; Yadav T; Khera PS
J Cancer Res Ther; 2021; 17(2):372-378. PubMed ID: 34121679
[TBL] [Abstract][Full Text] [Related]
11. MRI-Targeted or Standard Biopsy in Prostate Cancer Screening.
Eklund M; Jäderling F; Discacciati A; Bergman M; Annerstedt M; Aly M; Glaessgen A; Carlsson S; Grönberg H; Nordström T;
N Engl J Med; 2021 Sep; 385(10):908-920. PubMed ID: 34237810
[TBL] [Abstract][Full Text] [Related]
12. The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies.
Wegelin O; Exterkate L; van der Leest M; Kummer JA; Vreuls W; de Bruin PC; Bosch JLHR; Barentsz JO; Somford DM; van Melick HHE
Eur Urol; 2019 Apr; 75(4):582-590. PubMed ID: 30522912
[TBL] [Abstract][Full Text] [Related]
13. A Prospective Multicenter Comparison Study of Risk-adapted Ultrasound-directed and Magnetic Resonance Imaging-directed Diagnostic Pathways for Suspected Prostate Cancer in Biopsy-naïve Men.
Wagensveld IM; Osses DF; Groenendijk PM; Zijta FM; Busstra MB; Rociu E; Barentsz JO; Michiel Sedelaar JP; Arbeel B; Roeleveld T; Geenen R; Koeter I; van der Meer SA; Cappendijk V; Somford R; Klaver S; Van der Lely H; Wolters T; Hellings W; Leter MR; Van der Poel HG; Heijmink SWTPJ; Debruyne F; Immerzeel J; Leijte J; van Roermund J; Miclea R; Planken E; Vis AN; Jan de Jong I; Tijsterman J; Wolterbeek D; Claessen A; Vrijhof E; Nederend J; Van Leenders GJLH; Bangma CH; Krestin GP; Remmers S; Schoots IG;
Eur Urol; 2022 Sep; 82(3):318-326. PubMed ID: 35341658
[TBL] [Abstract][Full Text] [Related]
14. Design of a magnetic resonance imaging-based screening program for early diagnosis of prostate cancer: preliminary results of a randomized controlled trial-Prostate Cancer Secondary Screening in Sapienza (PROSA).
Messina E; La Torre G; Pecoraro M; Pisciotti ML; Sciarra A; Poscia R; Catalano C; Panebianco V
Eur Radiol; 2024 Jan; 34(1):204-213. PubMed ID: 37561183
[TBL] [Abstract][Full Text] [Related]
15. Predicting the Need for Biopsy to Detect Clinically Significant Prostate Cancer in Patients with a Magnetic Resonance Imaging-detected Prostate Imaging Reporting and Data System/Likert ≥3 Lesion: Development and Multinational External Validation of the Imperial Rapid Access to Prostate Imaging and Diagnosis Risk Score.
Peters M; Eldred-Evans D; Kurver P; Falagario UG; Connor MJ; Shah TT; Verhoeff JJC; Taimen P; Aronen HJ; Knaapila J; Montoya Perez I; Ettala O; Stabile A; Gandaglia G; Fossati N; Martini A; Cucchiara V; Briganti A; Lantz A; Picker W; Haug ES; Nordström T; Tanaka MB; Reddy D; Bass E; van Rossum PSN; Wong K; Tam H; Winkler M; Gordon S; Qazi H; Boström PJ; Jambor I; Ahmed HU
Eur Urol; 2022 Nov; 82(5):559-568. PubMed ID: 35963650
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic value of biparametric magnetic resonance imaging (MRI) as an adjunct to prostate-specific antigen (PSA)-based detection of prostate cancer in men without prior biopsies.
Rais-Bahrami S; Siddiqui MM; Vourganti S; Turkbey B; Rastinehad AR; Stamatakis L; Truong H; Walton-Diaz A; Hoang AN; Nix JW; Merino MJ; Wood BJ; Simon RM; Choyke PL; Pinto PA
BJU Int; 2015 Mar; 115(3):381-8. PubMed ID: 24447678
[TBL] [Abstract][Full Text] [Related]
17. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
[TBL] [Abstract][Full Text] [Related]
18. Bi- or multiparametric MRI in a sequential screening program for prostate cancer with PSA followed by MRI? Results from the Göteborg prostate cancer screening 2 trial.
Wallström J; Geterud K; Kohestani K; Maier SE; Månsson M; Pihl CG; Socratous A; Arnsrud Godtman R; Hellström M; Hugosson J
Eur Radiol; 2021 Nov; 31(11):8692-8702. PubMed ID: 33890152
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale.
Auvinen A; Rannikko A; Taari K; Kujala P; Mirtti T; Kenttämies A; Rinta-Kiikka I; Lehtimäki T; Oksala N; Pettersson K; Tammela TL
Eur J Epidemiol; 2017 Jun; 32(6):521-527. PubMed ID: 28762124
[TBL] [Abstract][Full Text] [Related]
20. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
